| Autor: |
Coşkun, G.P., Djikic, T., Hayal, T.B., Türkel, N., Yelekçi, K., Şahin, Fikrettin, Küçükgüzel, Ş.G. |
| Přispěvatelé: |
Coşkun, G.P., Djikic, T., Hayal, T.B., Türkel, N., Yelekçi, K., Şahin, Fikrettin, Küçükgüzel, Ş.G., Yeditepe Üniversitesi |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Popis: |
Cyclooxygenase enzymes play a vital role in inflammatory pathways in the human body. Apart from their relation with inflammation, the additional involvement of COX-2 enzyme with cancer activity was recently discovered. In some cancer types the level of COX-2 enzyme is increased indicating that this enzyme could be a suitable target for cancer therapy. Based on these findings, we have synthesized some new diflunisal thiosemicarbazides and 1,2,4-triazoles and tested them against androgen-independent prostate adenocarcinoma (PC-3), colon carcinoma (HCT-116), human breast cancer (T47D), breast carcinoma (MCF7) and human embryonic kidney (HEK-293) cell lines. Specifically, the diflunisal and thiosemicarbazide functionality are combined during the synthesis of original compounds anticipating a potency enhancement. Compounds 6, 10, 15 and 16 did not show cytotoxic effects for the HEK293 cell line. Among them, compounds 15 and 16 demonstrated anticancer activity for the breast cancer cell line T47D, whereas compounds 6 and 10 which are thiosemicarbazide derivatives displayed anti-tumourigenic activity against the PC-3 cell line, consistent with the literature. However, no activity was observed for the HCT-116 cancer cell line with the tested thiosemicarbazide derivatives. Only compound 16 displayed activity against the HCT-116 cell line. Therefore, it was speculated that the diflunisal and thiosemicarbazide functionalities potentiate anticancer activity on prostate cancer and the thiosemicarbazide functionality decreases the anticancer activity of diflunisal on colon cancer cell lines. In order to gain insight into the anticancer activity and COX-2 inhibition, molecular docking studies were carried out for COX-1 and COX-2 enzymes utilizing the newly synthesized compounds 15, and 16. Both 15 and 16 showed high selectivity and affinity toward COX-2 isozyme over COX-1, which is in agreement with the experimental results. © 2018 by the authors. 608381, 114S966 Consejo Nacional de Investigaciones CientÃficas y Técnicas H2020 Marie SkÅ?odowska-Curie Actions: FP7-MC-ITN Acknowledgments: This work was supported by The Scientific and Technical Research Council of Turkey (TÜBİTAK), Research Fund Project Number: 114S966. The authors are grateful to Jürgen Gross from the Institute of Organic Chemistry, University of Heidelberg, for his generous help on obtaining HR-EI/FAB mass spectra of the synthesized compounds. Diflunisal was supplied by Sanovel Pharmaceutical Industry Inc, İstanbul, Turkey. Teodora Djikic kindly acknowledges “Training in Neurodegeneration, Therapeutics, Intervention and Neurorepair” project number 608381 funded by Marie Sklodowska-Curie action, funding scheme: FP7-MC-ITN. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
